TG221: An Experimental Model for Liver Cancer Prevention and Treatment Approaches

Area of Science:

• Hepatology and Cancer Biology
• Molecular Oncology
• Translational Medicine

Background:

• Hepatocellular carcinoma (HCC) is a major cause of cancer death, often developing in cirrhotic livers due to chronic inflammation.
• MicroRNA (miRNA) dysregulation, specifically miR-221 upregulation and miR-199a-3p loss, drives liver carcinogenesis.
• The TG221 transgenic mouse model overexpressing miR-221 offers a platform for studying HCC mechanisms and interventions.

Purpose of the Study:

• To evaluate the TG221 mouse model for studying miRNA-driven hepatocarcinogenesis.
• To assess the efficacy of metformin and miRNA-based therapies in preventing and treating HCC.
• To explore novel therapeutic strategies including RNA-based and viral approaches.

Main Methods:

• Development and characterization of the TG221 transgenic mouse model overexpressing miR-221.
• Induction of cirrhosis using carbon tetrachloride (CCl4) in TG221 mice.
• Administration of metformin, anti-miR-221, miR-199a-3p mimics, palbociclib, sorafenib, and an oncolytic adenovirus.

Main Results:

• The TG221 model recapitulates HCC development, showing steatohepatitic injury and accelerated tumorigenesis.
• Metformin prevented tumor formation and suppressed PI3K/AKT/mTOR signaling during early fibrosis.
• miRNA-based interventions (inhibition/replacement) reduced tumor burden, restored tumor suppressors, and improved liver integrity.
• miR-199a-3p replacement synergized with palbociclib and overcame sorafenib resistance.
• A miR-199a-3p-responsive oncolytic adenovirus demonstrated tumor-selective replication with minimal toxicity.

Conclusions:

• The TG221 mouse is a valuable preclinical model for investigating miRNA-driven HCC.
• Metformin, miRNA inhibition, miRNA replacement, and miRNA-guided viral therapies are promising strategies for HCC precision prevention and treatment.